Edwards Lifesciences price target raised to $110 from $101 at Citi

Citi raised the firm's price target on Edwards Lifesciences to $110 from $101 and keeps a Buy rating on the shares. For Q2 earnings season, given "the skittish trading environment," the firm prefers higher-quality medtech stocks that may be positioned for a catch-up trade, the analyst tells investors in a preview.